Merck KGaA (OTCMKTS:MKKGY) Sees Large Volume Increase – Should You Buy?

Posted by Paula Ricardo on Aug 17th, 2026

Shares of Merck KGaA (OTCMKTS:MKKGY – Get Free Report) saw unusually-high trading volume on Monday . 164,620 shares changed hands during trading, an increase of 71% from the previous session’s volume of 96,264 shares.The stock last traded at $31.5910 and had previously closed at $31.58.

Wall Street Analysts Forecast Growth

MKKGY has been the topic of several recent analyst reports. Jefferies Financial Group began coverage on shares of Merck KGaA in a report on Tuesday, May 26th. They issued a “hold” rating on the stock. HSBC raised Merck KGaA to a “hold” rating in a research report on Monday, July 6th. Finally, Zacks Research raised Merck KGaA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

View Our Latest Stock Analysis on MKKGY

Merck KGaA Trading Down 0.0%

The company has a debt-to-equity ratio of 0.36, a current ratio of 1.51 and a quick ratio of 1.00. The company’s 50 day moving average is $32.18 and its two-hundred day moving average is $29.30. The firm has a market cap of $20.40 billion, a P/E ratio of 16.28, a PEG ratio of 2.61 and a beta of 0.98.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.